United Therapeutics (UTHR)
NASDAQ:UTHR
$179.12
-$1.37(-0.76%)
UTHRUnited Therapeutics
$179.12
-$1.37 (-0.76%)

United Therapeutics Stock Analysis & Ratings

United Therapeutics Stock Analysis Overview

Smart Score
6
Neutral
1
2
3
4
5
6
7
8
9
10
Learn more about TipRanks Smart Score
The United Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, Data-Driven rating system and does not include human intervention.

Stock Chart

UTHR
$179.12
-$1.37 (-0.76%)

UTHR Stock Stats

Previous Close$180.49
Open$181.05
Bid0 x 0
Ask0 x 0
Today’s Range$177.07 - $181.35
52-Week Range$98.37 - $212.62
Volume345.60K
Average Volume369.97K
Market Cap$8.02B
Beta0.51
P/E Ratio19.8
EPS9.03
Earnings DateAug 04, 2021

Company Description

United Therapeutics

United Therapeutics Corp. operates as a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening diseases. It markets and sells commercial therapies to treat pulmonary arterial hypertension and high-risk neuroblastoma. The firm also involves in the research and development of new indications and delivery devices for its product, and for the organ transplantation-related technologies. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.
Sector
Healthcare
Industry
Biotechnology
CEO
Martine A. Rothblatt
Employees
950
Address
1040 Spring Street, Silver Spring, MD, 20910, US

Financials


P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

UTHR FAQ

What was United Therapeutics’s price range in the past 12 months?
United Therapeutics lowest stock price was $98.37 and its highest was $212.62 in the past 12 months.
What is United Therapeutics’s market cap?
United Therapeutics’s market cap is $8.02B.
What is United Therapeutics’s price target?
The average price target for United Therapeutics is $236.00. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $276.00 ,the lowest forecast is $205.00. The average price target represents 31.76% Increase from the current price of $179.12.
What do analysts say about United Therapeutics?
United Therapeutics’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.
When is United Therapeutics’s upcoming earnings report date?
United Therapeutics’s upcoming earnings report date is Aug 04, 2021 which is next month.
How were United Therapeutics’s earnings last quarter?
United Therapeutics released its earnings results on May 05, 2021. The company reported $0.61 earnings per share for the quarter, missing the consensus estimate of $3.032 by -$2.422.
Is United Therapeutics overvalued?
According to Wall Street analysts United Therapeutics’s price is currently Undervalued.
Does United Therapeutics pay dividends?
United Therapeutics does not currently pay dividends.
What is United Therapeutics’s EPS estimate?
United Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does United Therapeutics have?
United Therapeutics has 44,800,000 shares outstanding.
What happened to United Therapeutics’s price movement after its last earnings report?
United Therapeutics reported an EPS of $0.61 in its last earnings report, missing expectations of $3.032. Following the earnings report the stock price went down -1.689%.
Which hedge fund is a major shareholder of United Therapeutics?
Among the largest hedge funds holding United Therapeutics’s share is Consonance Capital. It holds United Therapeutics’s shares valued at 93M.

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis